Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 7Melanoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rare Tumour 1Prostatic Neoplasms 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mouth Neoplasms 1Medulloblastoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Bevacizumab 2lenvatinib 1Platinum 1Pemetrexed 1Nivolumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × Clear all
NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Biocon Limited

Phase 1 Not yet recruiting
120 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡